Hemostemix CEO on autologous stem cell therapy and how it works with circulatory issues

In a recent InvestorIntel interview, Peter Clausi speaks with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc. (TSXV: HEM | OTC: HMTXD), about Hemostemix’s technology that uses patients own blood to treat ischemia in the circulatory system of the body.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Thomas said, “We take blood from patient’s arm. We fractionate out their stem cell from that blood.” He continued, “Then we culture them and change them from a raw stem cell into an angiogenic cell precursor that is programed to address ischemia in the circulatory system of the body. It is common in diabetics, in individuals who suffer from heart disease such as angina or ischemic cardiomyopathy, in wound care.”

Thomas stated that Hemostemix has treated more than 500 patients using the technology which is now in clinical trials. He added, “The second one we patented is NCP (Neural Cellular Precursor). This is a cell that can be used to treat stroke, diseases that have nerve damage.”

To watch the full interview, click here

About Hemostemix Inc.

Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.

On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled “Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow-up” which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years.

The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy.

To know more about Hemostemix Inc., click here

Disclaimer: Hemostemix Inc. is an advertorial member of InvestorIntel Corp.




Critical Materials Corner with Jack Lifton – Impact of Biden Admin on Rare Earths

In the first episode of the Critical Materials Corner with Jack Lifton, Jack talks about if there is going to be any change in the focus on critical materials under the Joe Biden administration.

In this InvestorIntel video, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Jack went on to explain the role of bureaucracy and the US Federal government to drive policies on critical materials to make the US independent of China for critical materials.

Speaking on the electric vehicles sector, Jack said, “The big drive in the US is to get the price of the batteries down.” He continued, “If I were an investor, I would be looking at batteries, battery management, battery raw materials, and also the raw materials for solar panels and wind turbines because these are big pushes by the US government.” He further added, “You can store energy with lithium, cobalt, nickel and manganese. But you can’t make anything move without rare earth permanent magnets.” Speaking on the Department of the Interior’s list of critical materials he explained why copper should be on the list.

To watch the full interview, click here




Lifton, Clausi, Cashin and Putnam on how the time for scandium is now

The Technology Metals Show hosts Jack Lifton and Peter Clausi talk to Peter Cashin, President and CEO of Imperial Mining Group Ltd. (TSXV: IPG) and George Putnam, President, CEO and Director of Scandium International Mining Corp. (TSX: SCY), about scandium, which is a critical material and the scandium market overall.

The full interview available exclusively to subscribers of the Technology Metals Show, this a promo clip from the panel’s discussion on the overall scandium market, commercial uses of scandium and the latest research and development that has been done in this area. George said, “Scandium has some unique aspects to it that make it well suited as an aluminum alloy along with some exciting uses in a number of areas specifically in battery technology.”

In the interview, Peter Cashin provided an update on the Imperial Mining’s Crater Lake Scandium-Rare Earth
property located in the Canada’s aluminum capital – Quebec.

To access the complete interview subscribe to the Technology Metals Show and get exclusive access to member-only content through this exclusive site. Or Log-In Here for the latest conversations, debates, updates and interviews with the leaders, thought leaders and investors focused on issues relating to sustainability in the critical materials sector.

For more information on the Technology Metals Show email us at info@technologymetals.com or reach us direct at +1 (416) 546-9233.




Co-founder Thomas Smeenk on the benefits of Hemostemix autologous stem cell therapy

In a recent InvestorIntel interview, Peter Clausi speaks with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc. (TSXV: HEM | OTC: HMTXD), about using Hemostemix’s patented autologous stem cell therapy platform to treat Ischemia and Angina with significant success in more than 500 patients.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Thomas went on to give an introduction about the origin of the company and talked about the strong management team and well known board members. “I have come across some good technologies and put together a team that have succeeded,” Thomas commented.

Thomas also provided an update on Hemostemix’s ACP-01 Phase 2 Clinical Trials. ACP-01 uses a patient’s own cells to restore blood flow to ischemic limbs and has the potential to treat a range of ischemic diseases.

To watch the full interview, click here

About Hemostemix Inc.

Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.

On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled “Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow-up” which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years.

The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy.

To know more about Hemostemix Inc., click here

Disclaimer: Hemostemix Inc. is an advertorial member of InvestorIntel Corp.




Peter Clausi with David Morgan on the rising interest in silver for 2021

In a recent InvestorIntel interview, Peter Clausi speaks with David Morgan of The Morgan Report, about investing in silver, the silver market and the source of the rising demand.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), David went on to say that he is bullish on silver and also commented on the gold to silver ratio. He said, “It is good for looking at long term trends and preview what you might use as an exit strategy.” He further added, “Gold has outperformed at this time, but silver is catching up and will continue to outperform.”

“Based on our current economic situation globally you should have some physical metal,” David commented. “Then you gain leverage by going into mining equities. A lot silver stocks have done quite well.”

To watch the complete interview, click here
Or to subscribe to The Morgan Report, click here: You Can Make a Killing Even In These Uncertain Markets (themorganreport.com)

To access InvestorChannel’s daily Silver Watchlist of the top 20 silver companies that David Morgan has selected for us to watch in the public markets, go to Silver – InvestorChannel




Douglas Hurst on Eclipse Gold’s merger with Northern Vertex designed to create a multi asset gold producer

In a recent InvestorIntel interview, Peter Clausi speaks with Douglas Hurst, Director at Eclipse Gold Mining Corp. (TSXV: EGLD), about Eclipse Gold’s at-market merger with Northern Vertex Mining to create a multi asset gold producer focused in the western USA.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Douglas went on to provide details of the merger and explained how the merger creates value for the shareholders supported by production and positive cash-flow from Northern Vertex’s Moss Mine and highly capable leadership, operations and exploration teams.

Speaking on the upside potential of the Moss mine, Douglas said, “It is right next to an operating mine.” He added, “You think of a kilometer and a half with half a million ounces and 10 kilometers of vein to explore, there is very significant upside here.”

To watch the full interview, click here

About Eclipse Gold Mining Corp.

Eclipse Gold Mining is exploring the district-scale Hercules gold property within Nevada’s Walker Lane trend. The Hercules property is located only a one-hour drive from Reno and appears to have all the characteristics of a large, low-sulphidation epithermal gold system. The company brings together a team with a track record of extensive M&A and nine successful buyouts totaling $4.6 billion.

About Northern Vertex

Northern Vertex Mining Corp. owns and operates the Moss Mine, currently the largest pure gold and silver mine in Arizona. Focused on low-cost gold and silver production, the company has experience across all areas of operations, mine development, exploration, acquisitions, and financing of mining projects. With operations at the flagship Moss, the company intends to consolidate additional producing and exploration gold assets within the Western US. Through mergers and acquisitions Northern Vertex’s corporate goal is to become a mid-tier gold producer.

To know more about Eclipse Gold Mining Corp., click here

Disclaimer: Eclipse Gold Mining Corp. is an advertorial member of InvestorIntel Corp.




Frank Basa on Canada Silver Cobalt’s recent high-grade gold mineralisation and silver vein discovery

In a recent InvestorIntel interview, Tracy Weslosky speaks with Frank Basa, CEO and Director of Canada Silver Cobalt Works Inc (TSXV: CCW | OTCQB: CCWOF), about the announcement of intersecting high-grade gold mineralisation and discovering a new, additional, high-grade silver vein at the Castle property.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Frank reviews Canada Silver Cobalt’s most recent discovery of gold and comments “…we found visible gold. I think nobody else has ever found it in the camp. Silver with the gold will make this deposit quite significant.

In a previous InvestorIntel interview, President & COO Matt Halliday stated that Canada Silver Cobalt has a resource of 7.5 million ounces at over 8000 grams per ton inferred. Commenting on how the new silver vein affects such previous statements, Frank said, “…we have a grade of about 250 ounces per ton in our inferred resource. It is unique, probably the highest grade resource that I am aware of globally.

To watch the full interview, click here

About Canada Silver Cobalt Works Inc.

Canada Silver Cobalt Works released the first-ever resource in the Gowganda Camp and greater Cobalt Camp in May 2020. A total of 7.56 million ounces of silver in Inferred resources comprising very high-grade silver (8,582 grams per tonne un-cut or 250.2 oz/ton) in 27,400 tonnes of material from two sections (1A and 1B) of the Robinson Zone beginning at a vertical depth of approximately 400 meters. The discovery remains open in all directions (1A and 1B are approximately 800 meters from the east-trending Capitol Mine workings) (mineral resources that are not mineral reserves do not have demonstrated economic viability) (refer to Canada Silver Cobalt Works Press Release May 28, 2020).

Canada Silver Cobalt’s flagship Castle mine and 78 sq. km Castle Property feature strong exploration upside for silver, cobalt, nickel, gold and copper in the prolific, past-producing Gowganda high-grade Silver District of Northern Ontario. With underground access at Castle, a pilot plant to produce cobalt-rich gravity concentrates on site, a processing facility (TTL Laboratories) in the town of Cobalt, and a proprietary hydrometallurgical process known as Re-2OX for the creation of technical grade cobalt sulphate as well as nickel-manganese-cobalt (NMC) formulations, Canada Silver Cobalt is strategically positioned to become a Canadian leader in the silver-cobalt space.

To know more about Canada Silver Cobalt Works Inc., click here

Disclaimer: Canada Silver Cobalt Works Inc. is an advertorial member of InvestorIntel Corp.